



# Financial Tear Sheet


## Corporate Profile

Tokai Pharmaceuticals is a biopharmaceutical company previously focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases. The ARMOR2 and ARMOR3-SV clinical trials of Tokai's drug candidate, galeterone, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) have been closed, with only patients in ARMOR2 long-term extension continuing treatment at this time. Plans remain in effect to present data from the ARMOR3-SV trial in a scientific forum once fully available and analyzed. Assessment of plans for galeterone, the ARDA platform and Tokai's AR-V7 assay work are underway at this time.

# Stock Information

## TKAI (Common Stock)

Exchange NASDAQ (US Dollar)  
Price **\$0.00**  
Change (%) 0.00 (NaN%)  
Volume 0  
52 Week Low \$0.00  
Market Cap \$13,802,350  
Rolling EPS 0.00  
PE Ratio 0  
Shares Outstanding 22,641,651  
Data as of 05/10/17 4:00 p.m. ET



# Recent Press Releases & Upcoming Events

12/22/16  
Tokai Pharmaceuticals and Otic Pharma Enter into Share Purchase Agreement  
09/08/16  
Tokai Pharmaceuticals Announces Review of Strategic Alternatives  
07/29/16  
Tokai Pharmaceuticals Announces Reduction in Force

There are currently no events scheduled.

# SEC Filings

Filing Date	Form
08/18/17	DEFA14A
08/18/17	DEF 14A
08/10/17	8-K
08/09/17	EFFECT

Data provided by Nasdaq. Minimum 15 minutes delayed.